Moreover, Yang et al. have confirmed the relationship between AKT and pulmonary fibrosis caused by COVID-19, showing that D-limonene has a potential therapeutic value in SARS-CoV-2-triggered pulmonary fibrosis by inhibiting the AKT pathway [121]. This evidence concerns the gene AKT1 and COVID-19.